Welcome to our dedicated page for Helius Med Technologies news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Med Technologies stock.
Helius Medical Technologies Inc (NASDAQ: HSDT) is a pioneering neurotechnology company focused on non-invasive therapies for neurological deficits. This page provides investors and healthcare professionals with essential updates on HSDT's progress, including regulatory milestones, clinical trial results, and strategic initiatives.
Discover the latest developments surrounding the Portable Neuromodulation Stimulator (PoNS), partnerships with medical institutions, and financial performance updates. Our curated news collection ensures you stay informed about HSDT's advancements in neuroplasticity-based treatments for conditions like multiple sclerosis and traumatic brain injury.
This resource aggregates official press releases, earnings reports, and market-related announcements. Key coverage areas: FDA regulatory updates, clinical study outcomes, executive leadership changes, and technology licensing agreements. Bookmark this page for streamlined access to material information impacting HSDT's position in the medical device sector.
Helius Medical Technologies, Inc. will release its first quarter 2024 financial results on May 13, 2024. The company, focused on innovative neuromodulation therapies, will discuss progress and plans for U.S. commercialization of PoNS® during a conference call hosted by its executives.
Helius Medical Technologies, Inc. announced the pricing of a $6.4 million public offering involving shares of Common Stock and Pre-Funded Warrants. The offering is expected to close on May 9, 2024, with net proceeds going towards operations and general corporate purposes.
Helius Medical Technologies, Inc., a neurotech company, announced the Centers for Medicare & Medicaid Services preliminary Medicare payment determinations for the PoNS Controller and Mouthpiece, with a public meeting scheduled for May 29, 2024. CMS proposed pricing based on cash pay rates, with the PoNS Mouthpiece capped at $3,075.53 and the PoNS Controller at $1,206.53. Helius plans to present at the meeting to advocate for higher reimbursement rates, intending to expand reimbursement and achieve positive cash flow.
FAQ
What is the current stock price of Helius Med Technologies (HSDT)?
What is the market cap of Helius Med Technologies (HSDT)?
